MAIA
insider transactionsMAIA Biotechnology, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Cluster buy signal: Multiple insiders at the same company buying around the same time — often a stronger signal than a single buy. 3 different insiders made open-market purchases in the last 90 days, totalling $203.8K.
Net shares · 90d
+149.7K
149.7K buy · 0 sell
Net value · 90d
$203.8K
$203.8K in · $0 out
Sentiment · 90d
Net buying
100% buying · 0% selling
Open-market trades · 90d
3
149.7K buy · 0 sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Buy·P
Vlad Vitoc KEY
Chief Executive Officer
$100.9K
72.7K sh · $1.39
Own +8%
-
Buy·P
Director
$100.2K
75.0K sh · $1.34
Own +5%
-
Buy·P
Chief Scientific Officer
$2.7K
2.0K sh · $1.35
Own +4%
-
Grant·A
Vlad Vitoc KEY
Chief Executive Officer
$0
800.0K sh
Own New
-
Grant·A
Head of Finance
$0
60.0K sh
Own New
-
Grant·A
Chief Scientific Officer
$0
400.0K sh
Own New
-
Grant·A
Vlad Vitoc KEY
Chief Executive Officer
$0
800.0K sh
Own New
-
Grant·A
Head of Finance
$0
30.0K sh
Own New
-
Grant·A
Chief Scientific Officer
$0
400.0K sh
Own New
-
Grant·A
Director
$0
27.3K sh
Own New
-
Grant·A
Director
$0
33.1K sh
Own New
-
Grant·A
Director
$0
28.6K sh
Own New
-
Grant·A
Director
$0
33.7K sh
Own New
-
Grant·A
Director
$0
27.3K sh
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 1, 2026 | Vlad Vitoc KEY | Buy P | 72.7K | $100.9K |
| Jun 1, 2026 | Stan Smith | Buy P | 75.0K | $100.2K |
| Jun 1, 2026 | Sergei Gryaznov | Buy P | 2.0K | $2.7K |
| May 29, 2026 | Vlad Vitoc KEY | Grant A | 800.0K | $0 |
| May 29, 2026 | Jeffrey C Himmelreich | Grant A | 60.0K | $0 |
| May 29, 2026 | Sergei Gryaznov | Grant A | 400.0K | $0 |
| Apr 10, 2026 | Vlad Vitoc KEY | Grant A | 800.0K | $0 |
| Apr 10, 2026 | Jeffrey C Himmelreich | Grant A | 30.0K | $0 |
| Apr 10, 2026 | Sergei Gryaznov | Grant A | 400.0K | $0 |
| Mar 31, 2026 | Jean-Manasse Theagene | Grant A | 27.3K | $0 |
| Mar 31, 2026 | Stan Smith | Grant A | 33.1K | $0 |
| Mar 31, 2026 | Cristian Luput | Grant A | 28.6K | $0 |
| Mar 31, 2026 | Ngar Yee Louie | Grant A | 33.7K | $0 |
| Mar 31, 2026 | Ramiro Guerrero | Grant A | 27.3K | $0 |
About MAIA insider trading
This page tracks insider transactions for MAIA Biotechnology, Inc. (MAIA) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.